GlaxoSmithKline Pharmaceuticals Limited
NSE:GLAXO.NS
2561.15 (INR) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q4 | 2018 Q3 | 2018 Q2 | 2018 Q1 | 2017 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 10,107.7 | 8,146.5 | 9,298 | 8,052.6 | 9,569.9 | 7,616.6 | 7,874.5 | 8,023 | 9,168.7 | 7,451 | 8,096.292 | 8,159.2 | 10,098.7 | 7,899.9 | 8,137.522 | 8,572 | 8,793.2 | 6,485.9 | 7,758.007 | 7,785.9 | 8,820.2 | 7,879.7 | 7,508.088 | 8,253.5 | 8,163.1 | 7,356.5 | 5,829 |
| Cost of Revenue
| 3,844.9 | 4,629.6 | 5,580.6 | 3,168.4 | 3,544.4 | 2,961.2 | 3,447.9 | 2,880.8 | 3,651 | 2,869 | 4,448.239 | 3,201.6 | 4,031.1 | 3,101.2 | 4,186.229 | 3,512.5 | 3,674.7 | 2,573.3 | 3,691.345 | 3,277.5 | 3,698.7 | 3,307.9 | 3,915.866 | 3,825.8 | 3,491.2 | 3,167.4 | 2,709.5 |
| Gross Profit
| 6,262.8 | 3,516.9 | 3,717.4 | 4,884.2 | 6,025.5 | 4,655.4 | 4,426.6 | 5,142.2 | 5,517.7 | 4,582 | 3,648.053 | 4,957.6 | 6,067.6 | 4,798.7 | 3,951.293 | 5,059.5 | 5,118.5 | 3,912.6 | 4,066.662 | 4,508.4 | 5,121.5 | 4,571.8 | 3,592.222 | 4,427.7 | 4,671.9 | 4,189.1 | 3,119.5 |
| Gross Profit Ratio
| 0.62 | 0.432 | 0.4 | 0.607 | 0.63 | 0.611 | 0.562 | 0.641 | 0.602 | 0.615 | 0.451 | 0.608 | 0.601 | 0.607 | 0.486 | 0.59 | 0.582 | 0.603 | 0.524 | 0.579 | 0.581 | 0.58 | 0.478 | 0.536 | 0.572 | 0.569 | 0.535 |
| Reseach & Development Expenses
| 0 | 0 | 25.437 | 0 | 0 | 0 | 19.099 | 0 | 0 | 0 | 18.285 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21.802 | 0 | 0 | 0 | 23.266 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 232.168 | 0 | 0 | 0 | 149.566 | 0 | 0 | 0 | 153.22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,789.455 | 0 | 0 | 0 | 1,811.19 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 1,093.632 | 0 | 0 | 0 | 1,091.234 | 0 | 0 | 0 | 1,276.88 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,382.295 | 0 | 0 | 0 | 1,203.64 | 0 | 0 | 0 | 0 |
| SG&A
| 1,538.6 | 1,375.6 | 1,325.8 | 1,290.1 | 1,678.5 | 1,566.6 | 1,240.8 | 1,325.3 | 1,529 | 1,580.6 | 1,430.1 | 1,555.6 | 1,702.3 | 1,604.1 | 1,566.6 | 1,592.1 | 1,540.1 | 1,519.2 | 3,171.75 | 1,666.9 | 1,474.7 | 1,428.1 | 3,014.83 | 1,255.5 | 1,395.3 | 1,259.8 | 0 |
| Other Expenses
| 3,214.3 | 356.4 | -876.822 | 281.1 | 282.1 | 364.4 | 2,901 | 3,019.3 | 3,112 | 3,251 | 1,997.91 | 3,158.2 | 93.5 | 105.2 | -319.522 | 140.2 | 90.4 | 152.4 | -631.899 | 165 | 158.8 | 308.1 | -259.759 | 165.8 | 150.1 | 177.8 | 137.5 |
| Operating Expenses
| 3,214.3 | 1,375.6 | 1,325.8 | 2,874.7 | 3,311.7 | 3,380.2 | 2,901 | 3,019.3 | 3,112 | 3,251 | 1,997.91 | 3,158.2 | 3,478.4 | 3,459.1 | 2,072.34 | 3,092.2 | 3,289.5 | 2,989.6 | 3,509.419 | 3,447.8 | 3,408.4 | 3,109.5 | 2,055.416 | 3,176.6 | 3,136.7 | 2,899 | 2,997.9 |
| Operating Income
| 3,048.5 | 2,141.3 | 2,391.6 | 2,290.6 | 2,995.9 | 1,639.6 | 1,802.2 | 2,357.1 | 2,625.4 | 1,607.1 | 1,783.039 | 1,902.6 | 2,589.2 | 1,339.6 | 1,878.953 | 1,967.3 | 1,829 | 923 | 557.243 | 1,060.6 | 1,713.1 | 1,462.3 | 1,536.806 | 1,251.1 | 1,535.2 | 1,290.1 | 121.6 |
| Operating Income Ratio
| 0.302 | 0.263 | 0.257 | 0.284 | 0.313 | 0.215 | 0.229 | 0.294 | 0.286 | 0.216 | 0.22 | 0.233 | 0.256 | 0.17 | 0.231 | 0.23 | 0.208 | 0.142 | 0.072 | 0.136 | 0.194 | 0.186 | 0.205 | 0.152 | 0.188 | 0.175 | 0.021 |
| Total Other Income Expenses Net
| 389.6 | 352.7 | 314.6 | -1,636.3 | -4.3 | 170.2 | 97.5 | -114.6 | -3.9 | -6.8 | 295.442 | -185 | 146.2 | 309.4 | -1,248.87 | 146.8 | -559.7 | 568.4 | 1,208.288 | -7,403.8 | 4,161 | 298.8 | 681.887 | 453.7 | 30 | 93 | 263 |
| Income Before Tax
| 3,438.1 | 2,494 | 2,706.2 | 654.3 | 2,991.6 | 1,809.8 | 1,899.7 | 2,242.5 | 2,621.5 | 1,600.3 | 2,078.481 | 1,717.6 | 2,735.4 | 1,649 | 630.083 | 2,114.1 | 1,269.3 | 1,491.4 | 1,765.531 | -6,343.2 | 5,874.1 | 1,761.1 | 2,218.693 | 1,704.8 | 1,565.2 | 1,383.1 | 384.6 |
| Income Before Tax Ratio
| 0.34 | 0.306 | 0.291 | 0.081 | 0.313 | 0.238 | 0.241 | 0.28 | 0.286 | 0.215 | 0.257 | 0.211 | 0.271 | 0.209 | 0.077 | 0.247 | 0.144 | 0.23 | 0.228 | -0.815 | 0.666 | 0.223 | 0.296 | 0.207 | 0.192 | 0.188 | 0.066 |
| Income Tax Expense
| 913.1 | 670.7 | 761.4 | 197.1 | 816.5 | 487.3 | 565.4 | 596.9 | 687.3 | 438 | 2,625.092 | 334.8 | 693 | 438.2 | 486.81 | 549 | 504.6 | 383.1 | 384.785 | 268.4 | 846.6 | 625.7 | 750.563 | 568.1 | 556.9 | 497.2 | 120.4 |
| Net Income
| 2,525 | 1,823.3 | 1,944.81 | 457.2 | 2,175.1 | 1,322.5 | 1,334.268 | 1,645.6 | 1,934.2 | 1,192.8 | -546.611 | 1,503.5 | 2,042.4 | 1,210.8 | 143.273 | 1,565.1 | 764.7 | 1,108.3 | 1,380.746 | -6,611.6 | 5,027.5 | 1,135.4 | 1,468.13 | 1,136.7 | 1,008.3 | 840.8 | 264.2 |
| Net Income Ratio
| 0.25 | 0.224 | 0.209 | 0.057 | 0.227 | 0.174 | 0.169 | 0.205 | 0.211 | 0.16 | -0.068 | 0.184 | 0.202 | 0.153 | 0.018 | 0.183 | 0.087 | 0.171 | 0.178 | -0.849 | 0.57 | 0.144 | 0.196 | 0.138 | 0.124 | 0.114 | 0.045 |
| EPS
| 14.91 | 10.76 | 11.48 | 2.7 | 12.84 | 7.81 | 7.88 | 9.71 | 11.42 | 7.04 | -3.23 | 8.17 | 12.06 | 7.15 | 0.85 | 9.24 | 4.51 | 6.54 | 8.14 | -39.03 | 29.68 | 6.7 | 8.66 | 6.71 | 5.95 | 4.96 | 1.56 |
| EPS Diluted
| 14.91 | 10.76 | 11.48 | 2.7 | 12.84 | 7.81 | 7.88 | 9.71 | 11.42 | 7.04 | -3.23 | 8.17 | 12.06 | 7.15 | 0.85 | 9.24 | 4.51 | 6.54 | 8.14 | -39.03 | 29.68 | 6.7 | 8.66 | 6.71 | 5.95 | 4.96 | 1.56 |
| EBITDA
| 3,609.4 | 2,305.4 | 2,572.6 | 2,461.7 | 3,177 | 1,803.2 | 1,974 | 2,521.2 | 2,789 | 1,765.3 | 1,936.499 | 2,081.3 | 2,914.9 | 1,834 | 2,353.516 | 2,284.6 | 2,139 | 1,719.9 | 789.578 | 1,408.9 | 2,098.9 | 1,961 | 2,142.913 | 1,537.3 | 1,800.4 | 1,581.5 | 334.3 |
| EBITDA Ratio
| 0.357 | 0.283 | 0.277 | 0.306 | 0.332 | 0.237 | 0.251 | 0.314 | 0.304 | 0.237 | 0.239 | 0.255 | 0.289 | 0.232 | 0.289 | 0.267 | 0.243 | 0.265 | 0.102 | 0.181 | 0.238 | 0.249 | 0.285 | 0.186 | 0.221 | 0.215 | 0.057 |